KUNPOONG BIO CO., LTD Introduces New Clinically Proven Blood Sugar Nutraceutical

GO2KA1™ is a breakthrough, naturally derived, patent-pending nutraceutical designed to define the benchmark for the glucose management category. Containing low molecular weight chitosan oligosaccharide bioactives derived from crab shells, clinically proven GO2KA1™ helps promotes both long-term blood sugar maintenance as well as short-term post-prandial responses via multiple mechanisms of action.

GO2KA1’s efficacy, high bioavailability, and safety have been demonstrated in short-term and long-term, randomized, double-blind, placebo-controlled human clinical trials involving healthy subjects, as well as pre-clinical research. 

The first smaller clinical trial, evaluated the effect of GO2KA1 on carbohydrate hydrolysis enzymes and showed that the postprandial blood glucose levels after meal are reduced. This is the first mechanism of action. The second larger clinical trial, evaluated the effect of GO2KA1 on insulin sensitivity, since we administrated GO2KA1 for 3 months and we evaluated what are the postprandial blood glucose levels after OGTT. This is the second mechanism of action.

GO2KA1 has a dual mechanism of action: 1) Inhibition of carbohydrate hydrolysis enzymes that results in management of glucose uptake from the small intestine after meal and 2) enhancement of insulin sensitivity for better utilization of glucose within fat and muscle cells.